A citation-based method for searching scientific literature

Nobuaki Ochi, Hiromichi Yamane, Tomoko Yamagishi, Nagio Takigawa, Yasumasa Monobe. Lung Cancer 2013
Times Cited: 10







List of co-cited articles
73 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations.
Doraid Alrifai, Sanjay Popat, Merina Ahmed, David Gonzalez, Andrew G Nicholson, John du Parcq, Tim Benepal. Lung Cancer 2013
15
70

ALK rearrangement in a pure squamous cell carcinoma: the challenge of detection of ALK rearrangement.
Hyojin Kim, Eunhyang Park, Yu Jung Kim, Jin-Haeng Chung. Virchows Arch 2013
11
50

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
50

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Neal I Lindeman, Philip T Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Dacic, Giuseppe Giaccone, Robert Brian Jenkins, David J Kwiatkowski, Juan-Sebastian Saldivar, Jeremy Squire,[...]. J Thorac Oncol 2013
577
40

ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma.
Jamie E Chaft, Natasha Rekhtman, Marc Ladanyi, Gregory J Riely. J Thorac Oncol 2012
36
40

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
Takashi Seto, Katsuyuki Kiura, Makoto Nishio, Kazuhiko Nakagawa, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Nobuyuki Yamamoto, Hiroshige Yoshioka, Masao Harada,[...]. Lancet Oncol 2013
432
40

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li,[...]. Cell 2007
40

ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung.
Anna Caliò, Alessia Nottegar, Eliana Gilioli, Emilio Bria, Sara Pilotto, Umberto Peretti, Stefania Kinspergher, Francesca Simionato, Serena Pedron, Sakari Knuutila,[...]. J Thorac Oncol 2014
35
40

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Alice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy, Daniel B Costa, Rebecca S Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott,[...]. J Clin Oncol 2009
40


ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Nobuaki Mamesaya, Kazuhisa Nakashima, Tateaki Naito, Takashi Nakajima, Masahiro Endo, Toshiaki Takahashi. BMC Cancer 2017
15
40

ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers.
Samuel J Klempner, David W Cohen, Daniel B Costa. J Thorac Oncol 2011
16
30

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, Sheheryar Kabraji, Mark M Awad, Ryohei Katayama, Amanda Pawlak, Mari Mino-Kenudson, Beow Y Yeap, Gregory J Riely,[...]. Clin Cancer Res 2013
393
30

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
30

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, A John Iafrate, Marileila Varella-Garcia, Stephen B Fox, Gregory J Riely, Benjamin Solomon, Sai-Hong I Ou, Dong-Wan Kim,[...]. Lancet Oncol 2012
937
30

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Robert C Doebele, Amanda B Pilling, Dara L Aisner, Tatiana G Kutateladze, Anh T Le, Andrew J Weickhardt, Kimi L Kondo, Derek J Linderman, Lynn E Heasley, Wilbur A Franklin,[...]. Clin Cancer Res 2012
803
30

ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.
Benjamin Solomon, Marileila Varella-Garcia, D Ross Camidge. J Thorac Oncol 2009
226
30

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
649
30

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer.
A J van der Wekken, R Pelgrim, N 't Hart, N Werner, M F Mastik, L Hendriks, E H F M van der Heijden, M Looijen-Salamon, A J de Langen, J Staal-van den Brekel,[...]. Clin Cancer Res 2017
53
30

ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
Florence Vergne, Gilles Quéré, Sophie Andrieu-Key, Renaud Descourt, Isabelle Quintin-Roué, Matthieu Talagas, Marc De Braekeleer, Pascale Marcorelles, Arnaud Uguen. Lung Cancer 2016
12
30


p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma.
Justin A Bishop, Julie Teruya-Feldstein, William H Westra, Giuseppe Pelosi, William D Travis, Natasha Rekhtman. Mod Pathol 2012
255
20

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
Natasha Rekhtman, Paul K Paik, Maria E Arcila, Laura J Tafe, Geoffrey R Oxnard, Andre L Moreira, William D Travis, Maureen F Zakowski, Mark G Kris, Marc Ladanyi. Clin Cancer Res 2012
282
20

Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Jennifer M Boland, Sibel Erdogan, George Vasmatzis, Ping Yang, Lori S Tillmans, Michele R Erickson Johnson, Xiaoke Wang, Lisa M Peterson, Kevin C Halling, Andre M Oliveira,[...]. Hum Pathol 2009
136
20

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
20

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
906
20

Identification of targetable FGFR gene fusions in diverse cancers.
Yi-Mi Wu, Fengyun Su, Shanker Kalyana-Sundaram, Nickolay Khazanov, Bushra Ateeq, Xuhong Cao, Robert J Lonigro, Pankaj Vats, Rui Wang, Su-Fang Lin,[...]. Cancer Discov 2013
490
20


Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.
Christina I Selinger, Toni-Maree Rogers, Prudence A Russell, Sandra O'Toole, Poyee Yip, Gavin M Wright, Zoe Wainer, Lisa G Horvath, Michael Boyer, Brian McCaughan,[...]. Mod Pathol 2013
116
20

Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays.
Tianhong Li, Martin K H Maus, Sonal J Desai, Laurel A Beckett, Craig Stephens, Eric Huang, Jack Hsiang, Gary Zeger, Kathleen D Danenberg, Stephanie H Astrow,[...]. J Thorac Oncol 2014
52
20

Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.
Lynette M Sholl, Stanislawa Weremowicz, Stacy W Gray, Kwok-Kin Wong, Lucian R Chirieac, Neal I Lindeman, Jason L Hornick. J Thorac Oncol 2013
120
20

Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
Hyojin Kim, Seol-Bong Yoo, Ji-Young Choe, Jin Ho Paik, Xianhua Xu, Hiroaki Nitta, Wenjun Zhang, Thomas M Grogan, Choon-Taek Lee, Sanghoon Jheon,[...]. J Thorac Oncol 2011
126
20

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Kentaro Inamura, Kengo Takeuchi, Yuki Togashi, Kimie Nomura, Hironori Ninomiya, Michiyo Okui, Yukitoshi Satoh, Sakae Okumura, Ken Nakagawa, Manabu Soda,[...]. J Thorac Oncol 2008
349
20

A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Maruja E Lira, Yoon-La Choi, Sun Min Lim, Shibing Deng, Donghui Huang, Mark Ozeck, Joungho Han, Ji Yun Jeong, Hyo Sup Shim, Byoung Chul Cho,[...]. J Mol Diagn 2014
86
20

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
20


An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators.
Murry W Wynes, Lynette M Sholl, Manfred Dietel, Ed Schuuring, Ming S Tsao, Yasushi Yatabe, Raymond R Tubbs, Fred R Hirsch. J Thorac Oncol 2014
126
20


ALK-Rearranged Squamous Cell Carcinoma of the Lung Treated with Two Lines of ALK Inhibitors.
Elena Bolzacchini, Alessandro Tuzi, Graziella Pinotti. J Thorac Oncol 2017
4
50

Targeting ALK: Precision Medicine Takes on Drug Resistance.
Jessica J Lin, Gregory J Riely, Alice T Shaw. Cancer Discov 2017
279
20

ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
Weijie Zhao, Yoon-La Choi, Ji-Young Song, Yazhen Zhu, Qing Xu, Feng Zhang, Lili Jiang, Ju Cheng, Guangjuan Zheng, Mao Mao. Lung Cancer 2016
38
20


ALK-rearranged squamous cell lung cancer: a case report.
Quan Zhang, Jinghui Wang, Shucai Zhang. Int J Clin Exp Pathol 2015
14
20


EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer.
Arjan Gower, Wei-Hsun Hsu, Shuo-Tse Hsu, Yisong Wang, Giuseppe Giaccone. Mol Oncol 2016
26
20

ALK-rearranged squamous cell carcinoma of the lung.
Yusuke Takanashi, Shogo Tajima, Shun Matsuura, Shin Koyama, Tsuyoshi Takahashi, Hiroshi Neyatani. Respirol Case Rep 2015
4
50

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.
Christine M Lovly, Nerina T McDonald, Heidi Chen, Sandra Ortiz-Cuaran, Lukas C Heukamp, Yingjun Yan, Alexandra Florin, Luka Ozretić, Diana Lim, Lu Wang,[...]. Nat Med 2014
202
20

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Ryohei Katayama, Alice T Shaw, Tahsin M Khan, Mari Mino-Kenudson, Benjamin J Solomon, Balazs Halmos, Nicholas A Jessop, John C Wain, Alan Tien Yeo, Cyril Benes,[...]. Sci Transl Med 2012
926
20

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
20

Comparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer.
DeSheng Xiao, Can Lu, Wei Zhu, QiuYan He, Yong Li, ChunYan Fu, JianHua Zhou, Shuang Liu, YongGuang Tao. Oncotarget 2016
12
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.